Kornimate/medical-research-clean huggingface dataset:
research on the key technology of burn wound treatment

Conditions: Burn

Summary: burns are common injuries in the daily life and wars. with the development of medical techniques, the mortality has been significantly reduced. however, the deformity and disability caused by hypertrophic scar have not been improved effectively since the wound repair technology is limited and controversial, especially on the early treatment of deep second degree burns. the prognosis of burns is of great difference. in recent years, the promotion of wound repairing technologies provides a new opportunity for improving the quality of wound healing and solving the problem of scar formation. although some new methods and techniques have shown significant efficacy in clinic, clinical researches with large samples conducted in multiple centers are still deficient, impeding the evaluation of their superiority. therefore, the current protocol focuses on the repair of deep second degree burns based on previous researches. there are four types of treatment protocols for wounds. patients were divided into four groups randomly, including regular dressing change group, controlled debridement + biological dressing covering group (xenogeneic acellular dermal matrix), controlled debridement + epidermal cell cultivation group, controlled debridement + bfgf treatment group. the wound healing rate, healing time and scar formation were observed. the availability and security were evaluated. further more, treatment guidelines and expert consensuses on deep second degree burn wounds were concluded. above studies are important to promote the treatment of deep second degree burns to be scientific, standardized and professional in china.


Eligibility criteria:
inclusion criteria: 1. area of deep second burn wound \>=10cm×10cm，total burn area ≤50% tbsa. 2. within 96 hours after burns and could be managed within 24 hours after included. 3. ages from 18 to 60. 4. no serious breathing, circulation and other systemic diseases, no surgical contraindications. 5. agrees to participate in this trial and has signed an informed consent form. exclusion criteria: 1. have severe inhalation injury or shock, or acute respiratory failure； 2. there are serious heart (especially the recent myocardial infarction, myocardial damage, etc.), brain, liver, kidney, lung and other organ disease; 3. susceptible to allergies； 4. islamic believers 5. pregnant women 6. other cases that are not suitable for study
effects of chronic smoking on circulating endothelial and platelet-derived microparticle

Conditions: Atherosclerosis

Summary: the investigators hypothesized that circulating emp is a useful surrogate marker of early stage of endothelial damage. to determine the effects of chronic smoking on circulating emp, from healthy volunteers who have habit of chronic smoking, peripheral blood is drawn at the time of flow-mediated dilatation (fmd) examination. spot urine is also collected. circulating emps are counted using flow-cytometry. after 2-week smoking cessation, the measurements were repeated.


Eligibility criteria:
inclusion criteria: * healthy individuals who have no coronary risk factors exclusion criteria: * hypertension * dyslipidemia * chronic kidney disease * liver dysfunction * obesity (bmi\>25.0) * cerebrovascular disease * other severe systemic diseases (cancer, inflammatory diseases, etc)
kaz954 alone and with pdr001, nzv930 and nir178 in advanced solid tumors

Conditions: Solid Tumors

Summary: the primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (mtd)/recommended dose (rd) for expansion of single agent kaz954 and kaz954 in combination with pdr001, nir178 and nzv930.

the purpose of this trial was to explore the clinical utility of several therapies in patients with advanced cancer. this is a multi-center, open-label phase i/ib study. the study consisted of a dose escalation part and a dose expansion part testing kaz954 as a single agent or kaz954 in combination with pdr001, nzv930 and nir178. the dose escalation part estimated the mtd and/or rd and tested different dosing schedules. the dose escalation arm kaz954 + nzv930 was not opened. the dose expansion part of the study was planned to use the mtd/rde determined in the dose escalation part to assess the activity, safety and tolerability of the investigational products in patients with specific types of cancer. the dose expansion part of the study was not started.

Eligibility criteria:
inclusion criteria: patients with metastatic and/or advanced malignancies not amenable to curative treatment by surgery. must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. patient must be willing to undergo a new tumor biopsy at screening and during the study. ecog performance status of \<2. exclusion criteria: presence of symptomatic central nervous system (cns) metastases, or cns metastases that require concurrent treatment - including surgery, radiation and/or corticosteroids. history of severe hypersensitivity reaction to any ingredient of study drug(s) and other mabs and/or their excipients. impaired cardiac function hiv known history of tuberculosis systemic chronic steroid therapy other protocol-defined inclusion/exclusion criteria may apply.

Keywords: solid tumors kaz954 pdr001 spartalizumab nir178 nzv930 immunotherapy phase i/ib
compare outcomes after high and low ligation of inferior mesenteric artery in colorectal cancer

Conditions: Colon Cancer

Summary: we aim comparing different outcomes between high and low tie ligation of inferior mesenteric artery in left colorectal cancer operable and elective surgeries.

colon cancer represents a significant clinical surgical burden, accounting for approximately 10% of all cancer cases. it is assumed that it is the second leading cause of cancer-related deaths worldwide. surgery and chemotherapy are considered the main lines of treatment. left colonic and rectal cancers represent approximately two-thirds of all colorectal malignancies. the mainstay of treatment is surgical resection, including tumor removal with adequate safety margins with adequate lymphadenectomy. several lifestyle factors contribute to the development of colorectal cancer, such as a high intake of processed meats and low intake of fruits and vegetables, a sedentary lifestyle, obesity, smoking, and excessive alcohol consumption. in colon and rectal cancer surgery, the approach toward the inferior mesenteric artery (ima) has always been debated among surgeons regarding the "high tie" and "low tie" techniques. according to the consensus statement of definitions of anorectal physiology and rectal cancer of the american society of colon and rectal surgeons (ascrs), a low tie of the ima is meant as a ligation after the origin of the left colic artery. in contrast, the high tie a ligation of the ima at its aortic root. high ligation of the ima for rectal and left colonic cancers may improve lymph node yield rate, thus facilitating more accurate tumor staging and better oncological outcomes. several studies have shown the importance of lymph node dissection up to the root of the ima in terms of better survival and precise staging. the high ligation also enables tension-free colonic anastomosis during low anterior resection. however, high ligation of the ima has been known to decrease blood flow to the anastomosis, increasing the risk of anastomotic leak. in contrast, the low-ligation technique allows for adequate blood supply to the colon proximal to the anastomotic stoma during low anterior resection that might prevent vascular inefficiency of the anastomotic marginal colic arteries and decrease the risk of anastomotic leak, especially in elderly patients. on the other hand, low ligation limits the opportunity for lymph node clearance at the origin of the ima. this incomplete lymphatic clearance may decrease survival while increasing the possibility of metastasis and cancer recurrence.

Eligibility criteria:
inclusion criteria: * every elective patient diagnosed with left-side colon or rectal cancer will be included in our study. exclusion criteria: * unfit patients with uncontrolled medical disease will be excluded. patients with acute intestinal obstruction (emergency cases) and patients with extremes of age above 75 or pediatric ages will be excluded.

Keywords: colon cancer high tie low tie inferior mesenteric artery
community-based intervention for fibromyalgia: a pilot trial

Conditions: Fibromyalgia

Summary: fibromyalgia (fm) is a multi-factorial chronic pain condition characterized by fluctuating and heterogeneous symptoms. this leads to both reduced patient function and quality of life and consequentially, significant economic burden on the society. although numerous pharmaceutical and multi-treatment approaches exist, there is lack of an integrated multidisciplinary model of care for these patients. such a system is hypothesized to be beneficial for the patients and would help them regain function and significantly improve their quality of life. the primary aim of this pilot clinical trial is to evaluate the effectiveness of an integrated community-based multidisciplinary model of care for fm patients in penticton and surrounding areas. the comprehensive 10 week intervention will provide care from a team of health care providers (psychiatrist, physiotherapist, certified exercise therapist, dietitian, rheumatologist, and mental health clinician). patients will also attend a peer led pain self-management support group provided by the arthritis society. the study aims at educating these patients about self-management of their symptoms such as chronic pain, weight, sleep and mood disorders. the integration of health care between the different providers will be achieved by "huddle" sessions that will be conducted on a monthly basis. the evaluation of the study outcomes will be based on the re-aim framework. data will be collected through patient questionnaires, healthcare utilization data, and interviews with providers. data analysis will involve thematic analysis of qualitative data and statistical methods for quantitative data.


Eligibility criteria:
inclusion criteria: * formal diagnosis of fm * resident of penticton or surrounding area * adults, aged 19 and older * fluent in english or bring a family member/friend to assist with translation * capacity to provide informed consent exclusion criteria: * patients with a severe and/or chronic medical or psychiatric condition that would impact ability to participate in the intervention * patients who are pregnant or lactating

Keywords: fibromyalgia community-based multidisciplinary
providence-1: study of rifalazil in chlamydia pneumoniae seropositive patients

Conditions: Peripheral Vascular Diseases; Intermittent Claudication

Summary: the objective of this study is to determine whether rifalazil can significantly increase peak walking time (pwt) in patients with peripheral arterial disease (pad).


Eligibility criteria:
inclusion criteria: * male or female patients between 40 and 80 years of age, inclusive. * the patient has seropositive evidence of chlamydia pneumoniae defined by immunoglobulin g antibody titers. * the patient has a diagnosis of intermittent claudication due to pad at screening. * the patient's maximal effort pwt is limited only by severe claudication symptoms. * if the patient is taking cilostazol or pentoxifylline and has been on a stable dose of the medication for at least 6 months prior to screening. patients who have recently discontinued medications for pad and/or intermittent claudication must "wash-out" for at least one month prior to screening. * the patient has been on a stable dose of statin therapy for at least 6 months prior to screening.patients who have recently discontinued statin therapy must "wash-out" for at least one month prior to screening. * male and female patients must agree to use an effective form of birth control throughout the study period. exclusion criteria: * the patient has critical limb ischemia as evidenced by ischemic rest pain, ulceration, or gangrene. * the patient has had a major amputation of the leg or any other amputation that limits walking ability. * the patient is planned for surgical/endovascular intervention for pad during the course of the study. * the patient has or is being treated or evaluated for tuberculosis. * the patient has a known immunodeficient state (e.g., positive for human immunodeficiency virus) or is being treated with immunosuppressive drugs including high dose steroids or cyclosporine. * the patient has an active infection requiring systemic or oral antibiotics. * the patient has an uncontrolled, unstable or recently diagnosed autoimmune disease, including but not limited to systemic lupus, inflammatory bowel disease, sarcoidosis, rheumatoid arthritis, or psoriasis. patients who develop autoimmune disease during the course of the study must be withdrawn. * the patient's pwt is limited by symptoms other than claudication (shortness of breath, fatigue, angina, or arthritis). * the patient has a history of alcohol abuse, illicit drug use or drug abuse or significant mental illness. * the patient has a known or suspected allergy to the study medication(s) or class of study medication (rifamycins) to be administered. * the patient chronically uses antibacterials or has previously received rifalazil or any rifamycin (e.g. rifampin). * the patient has uncontrolled hypertension (resting blood pressure \> 160/100 mm hg), uncontrolled moderate to severe congestive heart failure (chf), or uncontrolled arrhythmic disorders.

Keywords: intermittent claudication
efficacy of proton pump inhibitor for chronic cough caused by gastroesophageal reflux; double-blind, placebo-controlled, randomized clinical trial

Conditions: Chronic Cough Caused by Gastroesophageal Reflux

Summary: efficacy of proton pump inhibitor for chronic cough caused by gastroesophageal reflux; double-blind, placebo-controlled, randomized clinical trial


Eligibility criteria:
inclusion criteria: ages of 18 and 70 years had chronic cough of \>8 weeks in duration exclusion criteria: 1. abnormal chest x ray, pns view 2. previous surgical or endoscopic antireﬂux procedure 3. previous aerodigestive malignancy or barrett's oesophagus 4. current smokers or ex-smok-ers (deﬁned as those who quit smoking \<3 months prior to study enrolment or those who have quit, but have a 20 pack year smoking history) 5. malignancy history (lung cancer, esophageal cancer etc.) 6. upper respiratory infection within 8 weeks of study enrolment 7. currently using a ppi, h2 blocker, beta-blocker, angiotensin-converting enzyme inhibitor, corticosteroid, methylxanthine, inhaled beta-agonist, anti-inﬂammatory agent or anticholinesterase drug at time of enrolment

Keywords: chronic cough, proton pump inhibitor, gerd, nonacid reflux,
efficacy and safety of fosaprepitant dimeglumine in preventing chemotherapy-induced nausea and vomiting (mk-0517-031)

Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)

Summary: this study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-ht3) antagonist and a corticosteroid, a single 150 mg intravenous (iv) dose of fosaprepitant given on day 1 is superior to the control regimen of 5-ht3 antagonist and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (cinv) associated with moderately emetogenic chemotherapy (mec).


Eligibility criteria:
inclusion criteria: * has a histologically or cytologically confirmed malignant disease * is naive to moderately and highly emetogenic chemotherapy * is scheduled to receive a single iv dose of one or more mec agents on day 1, except for the combination of anthracycline and cyclophosphamide * has a predicted life expectancy of at least 4 months, and a karnofsky score of at least 60 indicating that the participant requires occasional assistance, but is able to care for most of his/her needs. * female of childbearing potential demonstrates a negative urine pregnancy test, and agrees to remain abstinent or use two acceptable forms of birth control for at least 14 days prior to study, throughout the study, and at least 1 month following last dose of study drug. exclusion criteria: * has vomited in the 24 hours prior to treatment day 1 * has symptomatic primary or metastatic symptomatic central nervous system malignancy causing nausea and/or vomiting * is scheduled to receive chemotherapy agent classified as highly emetogenic * has received or will receive total body irradiation, or radiation therapy to the abdomen, pelvis, head and neck in the week prior to treatment days 1 through day 6 of the treatment period * has illness or history of illness which might confound study results or pose unwarranted risk * known history of qt interval prolongation * uses illicit drugs or abuses alcohol * mentally incapacitated or has a significant emotional or psychiatric disorder * history of hypersensitivity to aprepitant, ondansetron or dexamethasone * pregnant or breast-feeding * has participated in a study with aprepitant or taken a non-approved (investigational) drug within the last 4 weeks * has concurrent condition, such as systemic fungal infection or uncontrolled diabetes, that precludes administration of dexamethasone.

Keywords: nk-1 receptor antagonist, cinv, emesis, mec
protective effect of coq10 against negative inflammatory response and organ dysfunction in cardiovascular surgery (panda v)

Conditions: Cardiovascular Disease

Summary: cardiovascular diseases are the leading causes of death and prescription drug use. research on certain dietary supplements looks promising as a way to help reduce risk factors. previous studies showed that coq10 levels were decreased in cardiovascular patients and worsening of mitochondrial dysfunction was observed. the overall objective of this study is to determine if supplementing with coq10 can reduce inflammatory risk factors in adults with cardiac surgery, independent of other dietary or physical activity changes.


Eligibility criteria:
inclusion criteria: * adult men and women * who receive cardiovascular surgery * agree to participate in the surgery and sign the informed consent form exclusion criteria: * pregnant or planning on getting pregnant during the study * contain a minimum of 2 traits of metabolic syndrome * refused to participate in the surgery and refused informed consent

Keywords: inflammatory response
high intensity resistance training in postmenopausal women (hirt)

Conditions: Post Menopause

Summary: menopause is defined as a permanent cessation of menstrual cycle for 12 months due to intrinsic diminution of ovarian oocytes among women in older age. globally reported mean age for menopause is 48.78 years (ranges from 46-52 years). menopausal age reported among asian and african population was lower as compared to european women . among postmenopausal women, age related various central nervous system, musculoskeletal, urogenital, metabolic and skin changes ensue along with osteoporosis (t-score = ≤ -2.5) and decreased bone mineral density due to estrogen deficiency that is directly associated with fragility fractures and disability among this age group. therefore, recruitment of older adults in resistance training program is crucial in inducing increases in muscle strength and ameliorating glucose tolerance and increased insulin sensitivity along with improvements in bmd and bmr.

physical activity is extremely crucial in maintaining quality of life and estrogen metabolism among postmenopausal women, owing to the increased risk of falls, age related decline in cardiopulmonary, musculoskeletal endurance and cognitive capacity. in pakistan, fitness of women specifically of postmenopausal age group is ignored due to some cultural norms. performance of physical activity in the form of resistance training (rt) is one of the best known methods to improve physical fitness in the elderly. so the current study is planned with objectives to determine effects of high intensity resistance training in postmenopausal women. supervised exercise training will be provided for 3 months and functional performance will be measured accordingly. after initial screening of postmenopausal women including history and anthropometric details, females meeting inclusion criteria and willing to participate in high intensity resistance exercise trial will be recruited in the study. after that; physical fitness, performance base testing for functional performance outcome measures and menqol assessment will be done at baseline and after 3 months. patients will perform resistance training twice a week, 40-50 min/session for 12 weeks respectively. it is hypothesized that supervised high intensity resistance training will improve functional performance, physical fitness and quality of life among postmenopausal women.

Eligibility criteria:
inclusion criteria: * postmenopausal women * age: 45-70 years * sedentary life style exclusion criteria: * high risk of fracture as calculated by who online frax tool. * presence/history of fragility fracture. * mmse \< 20 * systemic illness: hyperthyroidism, hyperparathyroidism, renal failure, any malignancy, extensive radiation exposure. * any orthopedic injury/disorder hindering performance of exercise. * not willing for exercise.
self-compassion to reduce diabetes distress in persons with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this study explored the effects of self-compassion intervention on diabetes distress and self-compassion.

this study tests the effects of a 12-week mindful self-compassion (msc) program in people with type 1 diabetes. eighty participants will be randomized to the msc program or be in a wait-list control group. measures of primary outcome are self-compassion and diabetes- distress. secondary outcomes are hemoglobin a1c, diabetes self-efficacy, stress and depression symptoms, and sleep quality. outcomes will be measured at baseline, 12 weeks (end of the program) and 24 weeks (post program).

Eligibility criteria:
inclusion criteria: * type 1 diabetes, age 18-30 * own computer or tablet with access to internet for meetings * willingness to complete all 6 sessions exclusion criteria: * history of self-harm or suicide attempt in the pat one year * severe diabetic complications such as dialysis or blindness * unstable depression, requiring ongoing medication adjustment within the last 3 months * a1c \> 11% * severe hypoglycemia requiring emergency room visit or hospitalization in the past 6 months * history of diabetic ketoacidosis requiring hospitalization in the past 3 months * pregnant or intend to get pregnant during the study timeframe

Keywords: self-compassion diabetes distress sleep